Nurix says pro­tein de­grad­er shows po­ten­tial in Walden­strom’s pa­tients in ear­ly tri­al

Nurix Ther­a­peu­tics’ BTK de­grad­er has elicit­ed re­spons­es in a small group of pa­tients with cer­tain can­cers, sup­port­ing the biotech’s claim that the drug could po­ten­tial­ly …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER